Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
11.5.2022 16:00:00 EEST | Business Wire | Press release
Alira Health (www.alirahealth.com), a global healthcare advisory and technology company, today announced the acquisition of RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction were not disclosed.
RedCrow was launched in 2016 by Brian Smith, a former Morgan Stanley financial advisor, and Jerry Harrison, an entrepreneur and member of the Rock and Roll Hall of Fame with Talking Heads. RedCrow mines the “wisdom of the crowd” to help find companies that resonate with an audience that may not only use a product but also invest in and realize a return from the company that invented it. This acquisition extends Alira Health’s ability to partner with patients across the lifecycle of drug and device development into the financing phase for early-stage pharma, MedTech, and healthcare services solutions.
“From personal experience, the founders at RedCrow recognize that not every drug or device receives the right investment,” said Gabriele Brambilla, CEO, and founder of Alira Health. “By reinventing and democratizing the way early-stage companies get funded, RedCrow helps more healthcare solutions come to market that can save patients’ lives. Alira Health already partners with patients across the development lifecycle. With RedCrow, we can now involve patients, their care circles, and other investors in the financing phase for new products that may also improve their care outcomes.”
RedCrow’s Brian Smith added, “We founded RedCrow with the belief that healthcare investing should be more immediate, transparent, and accessible, and that patients and their family members should be able to help fund future developments that may impact their own care. We embrace Alira Health’s mission to humanize healthcare and view our platform as a natural extension of Alira Health’s business model. At the same time, early-stage companies on the RedCrow platform can benefit from the breadth of Alira Health’s extensive services offering.”
Since its founding, RedCrow has marketed over 250 fundraises totaling $250 million. Recent success stories include HeartBeam (NASDAQ: BEAT), Sen Jam Pharmaceutical, Activ Surgical and Centerline Biomedical.
About RedCrow
Headquartered in Mill Valley, Calif., RedCrow, which was created because of the 2012 Jobs Act, is a direct investment and marketing platform for healthcare innovation, providing curated deal flow for all investors. RedCrow leverages both the industry experts to provide comprehensive analysis on healthcare startups, enabling a wide array of investors to help healthcare innovation succeed. When a startup joins RedCrow, it's equipped with the tools it needs, like virtual deal rooms, to market its company and investment opportunity. RedCrow leverages the knowledge of its advisory board, which includes financial, scientific, and medical professionals, along with its online community of investors, healthcare professionals, and patients to identify and support innovative companies.
Learn more at https://www.redcrow.com/home/what-we-do.html. Follow RedCrow on Twitter (@RedCrowCrowd) at https://twitter.com/RedCrowCrowd and LinkedIn at https://www.linkedin.com/company/redcrow-crowd/.
About Alira Health
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.
Learn more at https://alirahealth.com/. Follow Alira Health on Twitter (@AliraHealth) at https://twitter.com/alirahealth and LinkedIn at https://www.linkedin.com/company/alira-health/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005026/en/
Contact information
Corporate
Susan Irving
Vice President of Global Marketing
susan.irving@alirahealth.com
Media
David Schull
President, Russo Partners LLC
david.schull@russopartnersllc.com
Olipriya Das
Senior Account Executive, Russo Partners LLC
olipriya.das@russopartnersllc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 01:05:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs, including the Phase 3 KRAS G12D and TGFβR2×PD-1 studies already underway.” Details on rapid oral presentations at ESMO include: INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal Cancer (CRC) Session:
DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 21:35:00 EEST | Press release
The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization
TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 17:00:00 EEST | Press release
TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device. A live view of the device. The real device's screen opens in its own window on the developer's lapto
Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 17:00:00 EEST | Press release
Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor
METI and GX Acceleration Agency will hold GGX Finance Summit 202616.10.2026 16:00:00 EEST | Press release
On Monday, October 26th, the Ministry of Economy, Trade and Industry (METI) and GX Acceleration Agency will hold the GGX (Global GX) Finance Summit at Tokyo Prince Hotel and online. The Summit will advance discussions on transition finance, industry decarbonization, and the role of business and finance in driving decarbonization. It will also promote cooperation among government, industry, and the financial sector, and lead international rulemaking toward achieving both emission reductions and economic growth. Outline of GGX Finance Summit Date: October 26th, 2026 10:00 - 16:20 (JST, GMT+9:00) Venue: Tokyo Prince Hotel (Tokyo) (3-3-1 Shiba-Koen, Minato-ku, Tokyo 105-8560, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: GX Future Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation) Press Registration Please complete your registration by accessing the official
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
